卵巢癌新興生物標的診斷

本報告已在2011年12月21日停止出版。

簡介

目錄

Abstract

Worldwide, ovarian cancer (CaO) is the leading cause of death from gynecological cancer and the fourth most common cause of cancer death in women. In 2006, according to the American Cancer Society, 20,180 new cases of CaO will be diagnosed in the United States and 15,310 women will die from the disease. This high death rate results from the difficulty associated with detecting CaO at an early stage and the lack of effective therapies to treat advanced disease. As we discuss, physicians are unanimous in calling for the development of a diagnostic test that can identify CaO before it metastasizes. In this report, we examine the pathophysiology of CaO and describe current methods of screening for the cancer, the use of biomarkers to diagnose CaO, proteomic and genomic technologies that researchers are employing to identify and test biomarkers, emerging biomarkers, and the use of biomarkers to improve clinical trials of CaO treatments and ultimately to tailor treatment to the individual patient.

Table of Contents

• Overview
• Pathophysiology of Ovarian
  • Cancer
  • Characterization of Ovarian Epithelial
  • Tumors
• Spread of Ovarian
  • Cancer
  • Staging
• Prognostic
  • Factors
  • Tumor Stage
  • Peritoneal Fluid Cytology
  • Tumor Histology
  • Performance Status
  • Age
  • Volume of Residual Disease
  • CA-125 Levels
  • DNA Ploidy
• Current Ovarian Cancer
  • Screening
• Current Ovarian Cancer
  • Diagnosis
• Value of a Biomarker for Ovarian
  • Cancer
• Technologies Used to Identify Ovarian Cancer
  • Biomarkers
  • Proteomics
  • Genomics
• Emerging
  • markers
• Biomarker
  • Development
• Improving Clinical Trial
  • Design
• Patient-Tailored
  • Therapy
  • Outlook

• Table 1 International Federation of Gynecology and Obstetrics (FIGO) Staging System for Primary Carcinoma of the Ovary
• Table 2 Select Emerging Biomarkers for the Diagnosis of Ovarian Cancer
• Table 3 Serum Biomarkers Evaluated for Their Ability to Detect Ovarian Cancer
• Table 4 Ongoing U.S. Clinical Trials Investigating Screening and Diagnostic Methods for Ovarian Cancer

相關商品

生物標記相關市場調查報告書

生物標記相關合作契約
Biomarker Partnering Terms and Agreements
價格 : US $ 2695
出版日期 : 2012年02月

評估項目:心臟疾病的臨床實驗 - 替代評估項目及臨床生物指標的最大活用將是成功與否最大的決定性因素
Endpoints - Clinical Trials in Cardiovascular Disorders - Optimal Use of Surrogate Endpoints and Clinical Biomarkers are Key Determinants of Success
價格 : US $ 3500
出版日期 : 2012年01月

分子診斷﹕技術˙市場˙企業
Molecular Diagnostics - Technologies, Markets and Companies
價格 : US $ 5500
出版日期 : 2012年01月

Decision Resources, Inc.發行的生物科技相關市場調查報告書

以生物標記來預測自體免疫疾病生物療法的反應

Special Report: Use of Biomarkers to Predict Response to Biologics Therapy in Autoimmune Diseases

價格 : US $ 9200

出版日期 : 2011年06月

成為下一波一鳴驚人藥物的新一代治療用抗體的尋求

Pursuing Next-Generation Therapeutic Antibodies as the Next Source of Blockbuster Drugs

價格 : US $ 4600

出版日期 : 2011年06月

探索讓個人化醫療進化的資訊技術工具

Exploiting Information Technology Tools to Advance Personalized Medicine

價格 : US $ 4600

出版日期 : 2011年05月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!